Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

Next Previous
Trial Profile

A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulotaront (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals

Most Recent Events

  • 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
  • 05 Oct 2021 Results of an analysis assessing effects of SEP-363856 on negative symptoms in initial double-blind study and 6-month open-label extension study presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
  • 05 Oct 2021 Results of pooled analysis assessing the adverse event signals of this first agent in a novel drug class that differentiate it from the available class of atypical antipsychotics, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top